Cargando…

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis

Background: In order to relieve the financial burden of the patients in China, the Ministry of Health (MoH) conducted the first national price negotiation and successfully negotiated three expensive medicines including 2 targeted anticancer medicines (TAMs), icotinib and gefitinib. However, little e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Cong, Ung, Carolina Oi Lam, Wushouer, Haishaerjiang, Bai, Lin, Li, Xinyi, Guan, Xiaodong, Shi, Luwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kerman University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808358/ https://www.ncbi.nlm.nih.gov/pubmed/34273922 http://dx.doi.org/10.34172/ijhpm.2021.47

Ejemplares similares

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study
por: Guan, Xiaodong, et al.
Publicado: (2019)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017
por: Bai, Lin, et al.
Publicado: (2020)

Secular trend analysis of antibiotic utilisation in China’s hospitals 2011–2018, a retrospective analysis of procurement data
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022)

Medical insurance and healthcare utilization among the middle-aged and elderly in China: evidence from the China health and retirement longitudinal study 2011, 2013 and 2015
por: Zhou, Yue, et al.
Publicado: (2020)

Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending
por: Huang, Tao, et al.
Publicado: (2021)

Inpatient antibacterial use trends and patterns, China, 2013–2021
por: Wushouer, Haishaerjiang, et al.
Publicado: (2023)

Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis
por: Liu, Yanyan, et al.
Publicado: (2022)

The Impact of Sanming Healthcare Reform on Antibiotic Appropriate Use in County Hospitals in China
por: Hu, Lin, et al.
Publicado: (2022)

Outpatient Antibiotic Prescribing Patterns and Appropriateness for Children in Primary Healthcare Settings in Beijing City, China, 2017–2019
por: Wushouer, Haishaerjiang, et al.
Publicado: (2021)

Outpatient prescribing pattern for acute bronchitis in primary healthcare settings in China
por: Fu, Mengyuan, et al.
Publicado: (2021)

Safety of medication use during pregnancy in mainland China: based on a national health insurance database in 2015
por: Zhang, Jingyuan, et al.
Publicado: (2019)

Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China
por: Huang, Tao, et al.
Publicado: (2022)

The impact of physicians’ knowledge on outpatient antibiotic use: Evidence from China's county hospitals
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data
por: Yang, Yu, et al.
Publicado: (2023)

Protocol of a tailored educational intervention for general practitioners on potentially inappropriate medications among older patients at community healthcare institutions in Beijing, China: a cluster-randomised controlled trial
por: Fu, Mengyuan, et al.
Publicado: (2021)

Trends of Fixed-Dose Combination Antibiotic Consumption in Hospitals in China: Analysis of Data from the Center for Antibacterial Surveillance, 2013–2019
por: Wushouer, Haishaerjiang, et al.
Publicado: (2022)

Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study
por: Cai, Lele, et al.
Publicado: (2022)

Medication Use During Pregnancy in Mainland China: A Cross-Sectional Analysis of a National Health Insurance Database
por: Zhang, Jingyuan, et al.
Publicado: (2019)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
por: Zhu, Hong, et al.
Publicado: (2022)

Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China
por: Guan, Xiaodong, et al.
Publicado: (2018)

Antibiotic use and irrational antibiotic prescriptions in 66 primary healthcare institutions in Beijing City, China, 2015–2018
por: Taxifulati, Yumiti, et al.
Publicado: (2021)

Acid Suppression Use Among Infants in One Tertiary Children's Hospital in China, 2015–2018: A Retrospective Observational Study
por: Zhou, Yue, et al.
Publicado: (2021)

Study protocol for the evaluation of pharmacist-participated medication reconciliation at county hospitals in China: a multicentre, open-label, assessor-blinded, non-randomised, controlled study
por: Yu, Aichen, et al.
Publicado: (2022)

Trends and patterns of antibiotic consumption in China’s tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015
por: Wushouer, Haishaerjiang, et al.
Publicado: (2017)

Effectiveness of hierarchical medical system policy: an interrupted time series analysis of a pilot scheme in China
por: Hu, Huajie, et al.
Publicado: (2023)

Evaluation of prescription review and feedback policy on rational antibiotic use in primary healthcare settings in Beijing, China: a qualitative study using the Theoretical Domains Framework and the behaviour change wheel
por: Wushouer, Haishaerjiang, et al.
Publicado: (2023)

Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease
por: Dong, Pengxin, et al.
Publicado: (2018)

The Impact of Prescribing Monitoring Policy on Drug Use and Expenditures in China: A Multi-center Interrupted Time Series Study
por: Nie, Xiaoyan, et al.
Publicado: (2023)

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011–2021
por: Bai, Lin, et al.
Publicado: (2023)

Internationalization of traditional Chinese medicine: current international market, internationalization challenges and prospective suggestions
por: Lin, Annie Xianghong, et al.
Publicado: (2018)

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review
por: He, Zixuan, et al.
Publicado: (2023)

Prevalence and Trend of Major Transfusion-Transmissible Infections among Blood Donors in Western China, 2005 through 2010
por: Song, Yan, et al.
Publicado: (2014)

Policy analysis of system responses to addressing and reversing the obesity trend in China: a documentary research
por: Xue, Yan, et al.
Publicado: (2023)

Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis
por: Sun, Yan, et al.
Publicado: (2022)

The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis
por: Ding, Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c17nks9vku9ss3ed3b1ad5c4ri